Medacta Continues Ascent in First Half of 2022

Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021.

Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta's growth. COVID restrictions and hospital staffing shortages in the U.S. and Australia offset some of the company's gains, however.

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us